Fusion Pharmaceuticals Inc. Contracts & Agreements

Employment Agreement between the Company and Eric Burak, Ph.D. (dated as of December 18, 2023) (Filed With SEC on March 20, 2024)

Amendment to the Employment Agreement, by and between Fusion Pharmaceuticals Inc. and Eric Burak, dated as of March 18, 2024 (Filed With SEC on March 19, 2024)

Arrangement Agreement dated as of March 18, 2024, among Fusion Pharmaceuticals Inc., AstraZeneca AB and 15863210 Canada Inc (Filed With SEC on March 19, 2024)

License Agreement, dated February 16, 2024, among Fusion Pharmaceuticals Inc., Universitt Heidelberg and Euratom represented by the European Commission, Joint Research Centre (Filed With SEC on February 16, 2024)

Amendment No. 1 to Open Market Sale AgreementSM, dated January 19, 2024, by and between the Company and Jefferies LLC (Filed With SEC on January 19, 2024)

Registration Rights Agreement, dated May 10, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on May 11, 2023)

Securities Purchase Agreement, dated May 10, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on May 11, 2023)

Registration Rights Agreement, dated February 13, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on February 14, 2023)

Securities Purchase Agreement, dated February 13, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on February 14, 2023)

Option and Asset Purchase Agreement by and between Fusion Pharmaceuticals Inc. and RadioMedix, Inc., dated November 14, 2022 (Filed With SEC on February 14, 2023)

Option and Asset Purchase Agreement by and between Fusion Pharmaceuticals Inc. and RadioMedix, Inc., dated November 14, 2022 (Filed With SEC on February 13, 2023)

Securities Purchase Agreement, dated February 13, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on February 13, 2023)

Registration Rights Agreement, dated February 13, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on February 13, 2023)

Second Amendment to Loan and Security Agreement, dated as of September 21, 2022, by and between Oxford Finance LLC and the Company (Filed With SEC on November 8, 2022)

Consent and First Amendment to Loan and Security Agreement, dated as of August 23, 2022, by and between Oxford Finance LLC and the Company (Filed With SEC on November 8, 2022)

Loan and Security Agreement, dated as of April 4, 2022, by and between Oxford Finance LLC and the Company (Filed With SEC on August 9, 2022)

Employment Agreement between the Company and Christopher Leamon, Ph.D., dated as of November 1, 2021 (Filed With SEC on March 17, 2022)

Employment Agreement between the Company and Mohit Rawat, dated as of September 27, 2021 (Filed With SEC on March 17, 2022)

Amendment No. 3 to Collaboration Agreement, dated August 12, 2021, by and between TRIUMF Innovations Inc. and TRIUMF JV and the Company (Filed With SEC on November 9, 2021)

Amendment No. 2 to Collaboration Agreement, dated July 27, 2021, by and between TRIUMF Innovations Inc. and TRIUMF JV and the Company (Filed With SEC on November 9, 2021)

Amendment No. 1 to Collaboration Agreement, dated June 28, 2021, by and between TRIUMF Innovations Inc. and TRIUMF JV and the Company (Filed With SEC on November 9, 2021)

Collaboration Agreement, dated December 10, 2020, by and between TRIUMF Innovations Inc. and TRIUMF JV and the Company (Filed With SEC on November 9, 2021)

Lease Agreement by and between Fusion Pharmaceuticals Inc. and McMaster University, dated June 1, 2021 (Filed With SEC on June 3, 2021)

Amendment No. 1 to Employment Agreement between the Company and John Valliant, dated as of February 19, 2021 (Filed With SEC on March 25, 2021)

First Amendment to Lease Agreement, dated as of March 16, 2021, by and between Fort Hill Square 2 Owner LLC and the Company (Filed With SEC on March 25, 2021)

Amendment No. 2 to Asset Purchase Agreement, dated February 8, 2021, by and between Rainier Therapeutics, Inc. and the Company (Filed With SEC on March 25, 2021)

Amendment No. 1 to Employment Agreement between the Company and Eric Burak, dated as of February 19, 2021 (Filed With SEC on March 25, 2021)

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 25, 2021)

Asset Purchase Agreement by and between Fusion Pharmaceuticals Inc. and Ipsen Pharma SAS, dated March 1, 2021 (Filed With SEC on March 2, 2021)

Amendment No. 1 to Asset Purchase Agreement, dated October 8, 2020, by and between Fusion Pharmaceuticals Inc. and Rainier Therapeutics, Inc (Filed With SEC on November 10, 2020)

Strategic Collaboration Agreement by and between Fusion Pharmaceuticals Inc. and AstraZeneca UK Limited, dated October 30, 2020 (Filed With SEC on November 2, 2020)

2020 Stock Option and Incentive Plan and forms of award agreements thereunder (Filed With SEC on June 22, 2020)

Form of Underwriting Agreement (Filed With SEC on June 22, 2020)

Form of Specimen Common Share Certificate (Filed With SEC on June 22, 2020)

Senior Executive Cash Incentive Bonus Plan (Filed With SEC on June 22, 2020)

2020 Employee Share Purchase Plan (Filed With SEC on June 22, 2020)

Form of Officer Indemnification Agreement (Filed With SEC on June 22, 2020)

Form of Director Indemnification Agreement (Filed With SEC on June 22, 2020)

Employment Agreement between the Registrant and John Valliant, PhD, to be in effect upon the closing of this offering (Filed With SEC on June 22, 2020)

Employment Agreement between the Registrant and John Crowley, CPA, to be in effect upon the closing of this offering (Filed With SEC on June 22, 2020)

Employment Agreement between the Registrant and Eric Burak, PhD, to be in effect upon the closing of this offering (Filed With SEC on June 22, 2020)

Employment Agreement between the Registrant and James OLeary, MD, to be in effect upon the closing of this offering (Filed With SEC on June 22, 2020)

Amended and Restated Investors Rights Agreement among the Registrant and certain of its shareholders, dated March 25, 2019 (Filed With SEC on June 5, 2020)

Supply Agreement, dated as of January 17, 2019, by and between the Centre for Probe Development and Commercialization Inc. and the Registrant (Filed With SEC on June 5, 2020)

Master Services Agreement, dated as of February 22, 2017, by and between the Centre for Probe Development and Commercialization Inc. and the Registrant (Filed With SEC on June 5, 2020)

Asset Purchase Agreement, dated as of March 10, 2020, by and between Rainier Therapeutics, Inc., Fortis Advisors LLC and the Registrant (Filed With SEC on June 5, 2020)

License Agreement, dated as of December 19, 2016, by and between ImmunoGen, Inc. and the Registrant, as amended (Filed With SEC on June 5, 2020)

License Agreement, dated as of February 22, 2017, by and between the Centre for Probe Development and Commercialization Inc. and the Registrant (Filed With SEC on June 5, 2020)

Lease Agreement, dated as of August 1, 2018, by and between McMaster University and the Registrant (Filed With SEC on June 5, 2020)

Lease Agreement, dated as of October 1, 2019, by and between Fort Hill Square 2 Owner LLC and the Registrant (Filed With SEC on June 5, 2020)

2017 Equity Incentive Plan, as amended, and forms of award agreements thereunder (Filed With SEC on June 5, 2020)

Form of Class B Preferred Share Purchase Warrants (Filed With SEC on June 5, 2020)

Form of Class B Preferred Exchangeable Share Purchase Warrant (Filed With SEC on June 5, 2020)

Category

Industry

Companies

Contracts

Fusion Pharmaceuticals Inc. Contracts & Agreements